Original Article

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy†

Results of Cancer and Leukemia Group B (CALGB) 9782

  1. J. Paul Monk MD1,‡,*,
  2. Susan Halabi PhD2,3,
  3. Joel Picus MD4,
  4. Arif Hussain MD5,
  5. George Philips MD6,
  6. Ellen Kaplan PhD2,
  7. Tim Ahles PhD7,
  8. Lin Gu PhD2,
  9. Nicholas Vogelzang MD8,
  10. William K. Kelly MD9,
  11. Eric J. Small MD10,
  12. for the Cancer and Leukemia Group B1

Article first published online: 16 DEC 2011

DOI: 10.1002/cncr.26732

Issue

Cancer

Cancer

Volume 118, Issue 17, pages 4139–4147, 1 September 2012

Additional Information

How to Cite

Monk, J. P., Halabi, S., Picus, J., Hussain, A., Philips, G., Kaplan, E., Ahles, T., Gu, L., Vogelzang, N., Kelly, W. K., Small, E. J. and for the Cancer and Leukemia Group B (2012), Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy. Cancer, 118: 4139–4147. doi: 10.1002/cncr.26732

Author Information

  1. 1

    Division of Oncology, Department of Medicine, The Ohio State University School of Medicine, Columbus, Ohio

  2. 2

    Cancer and Leukemia Group B Statistical and Data Center, Duke University Medical Center, Durham, North Carolina

  3. 3

    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina

  4. 4

    Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

  5. 5

    Division of Oncology, Department of Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland

  6. 6

    Division of Oncology, Department of Medicine, Georgetown University, Washington, District of Columbia

  7. 7

    Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York

  8. 8

    Division of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

  9. 9

    Division of Oncology, Department of Medicine, Thomas Jefferson Kimmel Cancer Center, Philadelphia, Pennsylvania

  10. 10

    Division of Oncology, Department of Medicine, University of California at San Francisco, San Francisco, California

  1. ‡

    Fax: (614) 293-7525

*Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, A433 B Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210-1240

  1. †

    The following institutions participated in this study: Cancer and Leukemia Group B Statistical Office, Durham, NC (Daniel J. Sargent, PhD, supported by CA33601); Christiana Care Health Services, Inc., CCOP, Wilmington, DE (Stephen S. Grubbs, MD, supported by CA45418); Dana Farber Cancer Institute, Boston, MA (Harold J. Burstein, MD, PhD, supported by CA32291); North Shore University Hospital, Manhasset, NY; The Ohio State University Medical Center, Columbus, OH (Clara D. Bloomfield, MD, supported by CA77658); Hematology-Oncology Associates of Central New York CCOP, Syracuse, NY (Jeffrey Kirshner, MD, supported by CA45389); University of California at San Francisco, San Francisco, CA (Charles Ryan, MD, supported by CA60138); University of Chicago, Chicago, IL (Hedy L. Kindler, MD, supported by CA41287); University of Minnesota, Minneapolis, MN (Bruce A. Peterson, MD, supported by CA16450); University of Nebraska Medical Center, Omaha, NE (Anne Kessinger, MD, supported by CA77298); University of North Carolina at Chapel Hill, Chapel Hill, NC (Thomas Shea, MD, supported by CA47559); University of Vermont, Burlington, VT (Steven M. Grunberg, MD, supported by CA77406); Wake Forest University School of Medicine, Winston-Salem, NC (David D. Hurd, MD, supported by CA03927); Washington University School of Medicine, St. Louis, MO (Nancy L. Bartlett, MD, supported by CA77440); and Western Pennsylvania Cancer Institute, Pittsburgh, PA (John Lister, MD).

  2. ‡

    Fax: (614) 293-7525

Publication History

  1. Issue published online: 20 AUG 2012
  2. Article first published online: 16 DEC 2011
  3. Manuscript Accepted: 17 OCT 2011
  4. Manuscript Revised: 7 OCT 2011
  5. Manuscript Received: 25 AUG 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (296K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kyle O. Rove, E. David Crawford, Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer, Current Opinion in Urology, 2013, 23, 3, 208

    CrossRef

View Full Article (HTML) Get PDF (296K)